Back to School: How biopharma can reboot drug development. Access exclusive analysis here
CELG fell $5.96 to $64.22 on 21.6 million shares on Thursday after reporting 3Q07 revenues that missed the Street
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury